We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-19.25%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$585M
AUM Growth
-$382M
(-40%)
Cap. Flow
-$229M
Cap. Flow
% of AUM
-39.19%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
429
New
88
Increased
84
Reduced
102
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Energy Transfer Partners
ET
|
+$50.2M |
| 2 |
Enterprise Products Partners
EPD
|
+$8.56M |
| 3 |
Oneok
OKE
|
+$8.36M |
| 4 |
AM
ANTERO MIDSTREAM PARTNERS LP
AM
|
+$3.06M |
| 5 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$77.3M |
| 2 |
Marathon Petroleum
MPC
|
+$28.8M |
| 3 |
EEP
Enbridge Energy Partners
EEP
|
+$23.6M |
| 4 |
Phillips 66
PSX
|
+$16.9M |
| 5 |
Williams Companies
WMB
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 82.73% |
| 2 | Healthcare | 7.29% |
| 3 | Utilities | 2.06% |
| 4 | Financials | 0.12% |
| 5 | Technology | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ASRT
151
DELISTED
Assertio
ASRT
| $266K | 0.05% |
+1,228
| New | +$369K |
|
152
Iovance Biotherapeutics
IOVA
$2.23B
| $266K | 0.05% |
30,077
-6,043
| -17% | -$58.3K |
|
153
ProQR Therapeutics
PRQR
$243M
| $263K | 0.04% |
+16,682
| New | +$306K |
|
|
ALLK
154
DELISTED
Allakos
ALLK
| $262K | 0.04% |
+5,014
| New | +$251K |
|
|
DRNA
155
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $261K | 0.04% |
+24,457
| New | +$322K |
|
156
Arrowhead Research
ARWR
$12.1B
| $252K | 0.04% |
20,261
-19,285
| -49% | -$264K |
|
157
TG Therapeutics
TGTX
$8.58B
| $252K | 0.04% |
61,557
+27,134
| +79% | +$135K |
|
158
Wave Life Sciences
WVE
$1.12B
| $252K | 0.04% |
+5,986
| New | +$266K |
|
|
AMRS
159
DELISTED
Amyris Inc.
AMRS
| $251K | 0.04% |
+75,294
| New | +$434K |
|
160
Marker Therapeutics
MRKR
$20.3M
| $250K | 0.04% |
+4,496
| New | +$328K |
|
161
Viking Therapeutics
VKTX
$4.04B
| $247K | 0.04% |
32,311
-7,649
| -19% | -$91.5K |
|
|
DCPH
162
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $247K | 0.04% |
11,773
+355
| +3% | +$8.73K |
|
|
ITCI
163
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $246K | 0.04% |
21,613
-645
| -3% | -$10.4K |
|
164
Inovio Pharmaceuticals
INO
$79.8M
| $242K | 0.04% |
5,033
-3,634
| -42% | -$221K |
|
165
Novavax
NVAX
$1.23B
| $241K | 0.04% |
6,560
-8,046
| -55% | -$312K |
|
|
OPTN
166
DELISTED
OptiNose
OPTN
| $238K | 0.04% |
+2,555
| New | +$365K |
|
167
Cytokinetics
CYTK
$11B
| $237K | 0.04% |
37,487
-12,590
| -25% | -$92.4K |
|
168
Fate Therapeutics
FATE
$281M
| $235K | 0.04% |
18,340
-19,754
| -52% | -$275K |
|
|
APTX
169
DELISTED
Aptinyx Inc. Common Stock
APTX
| $230K | 0.04% |
+13,905
| New | +$329K |
|
|
TCDA
170
DELISTED
Tricida, Inc. Common Stock
TCDA
| $227K | 0.04% |
+9,633
| New | +$277K |
|
|
IMMU
171
DELISTED
Immunomedics Inc
IMMU
| $226K | 0.04% |
15,848
-3,818
| -19% | -$75.8K |
|
172
NRG Energy
NRG
$29.8B
| $224K | 0.04% |
5,650
| – | – |
|
|
LJPC
173
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $224K | 0.04% |
23,806
+8,545
| +56% | +$129K |
|
174
Geron
GERN
$911M
| $216K | 0.04% |
216,245
+94,899
| +78% | +$144K |
|
175
Akebia Therapeutics
AKBA
$327M
| $211K | 0.04% |
38,183
-3,854
| -9% | -$30.2K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, Virtus ETF Advisers held 429 positions worth $585M, down 40% from $968M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Virtus ETF Advisers withdrew a net $229M in Q4 2018, closing 122 positions and reducing 102 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $77.3M position sold in full.
By sector, the portfolio is most concentrated in Energy at 83% of assets, up from 68% a quarter earlier, followed by Healthcare and Utilities.
Against the trend, Virtus ETF Advisers opened a new position in Amyris Inc. worth $251K.
- Virtus ETF Advisers's largest Q4 2018 buy was Amyris Inc.: 75,294 shares worth $251K.
- Virtus ETF Advisers added most to Energy Transfer Partners in Q4 2018, an estimated $50.2M increase.
- Virtus ETF Advisers's biggest Q4 2018 reduction was Marathon Petroleum, cutting an estimated $28.8M.
- Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $77.3M.
- Virtus ETF Advisers's ten largest holdings make up 61% of its $585M portfolio in Q4 2018.
- Virtus ETF Advisers opened 88 new positions and closed 122 in Q4 2018.
- Virtus ETF Advisers's portfolio value fell 40% quarter-over-quarter to $585M.
Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.